These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36504020)

  • 1. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
    Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
    Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society.
    Tomimaru Y; Eguchi H; Shimomura Y; Kitamura T; Inoue Y; Nagakawa Y; Ohba A; Onoe S; Unno M; Hashimoto D; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Uemura K; Kimura Y; Satoi S; Takeyama Y;
    J Gastroenterol; 2023 Aug; 58(8):790-799. PubMed ID: 37329351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M
    Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
    Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
    BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenocarcinoma: A retrospective study.
    Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
    Medicine (Baltimore); 2024 May; 103(21):e38292. PubMed ID: 38788030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
    Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
    BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
    Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
    J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
    Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
    Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis.
    Yen CC; Shan YS; Chao YJ; Liao TK; Chen IS; Huang HY; Liu IT; Yen CJ
    BMC Cancer; 2021 Jul; 21(1):796. PubMed ID: 34243732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an Immune-Related BAT Signature for Predicting Adjuvant Chemotherapy Response and Overall Survival in Patients with Resected Ductal Adenocarcinoma of the Pancreas.
    Pu N; Chen Q; Yin H; Zhang J; Zhao G; Habib JR; Chen J; Yu J; Lou W; Wu W
    J Gastrointest Surg; 2022 Apr; 26(4):869-886. PubMed ID: 35059985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Relative Dose Intensity of Adjuvant Chemotherapy With S-1 on Pancreatic Ductal Adenocarcinoma.
    Matsushima H; Adachi T; Hidaka M; Yamashita M; Hamada T; Fukui S; Tanaka T; Imamura H; Yoshino K; Kugiyama T; Kitasato A; Hara T; Soyama A; Kobayashi K; Sumida Y; Kuroki T; Eguchi S
    Anticancer Res; 2022 Jun; 42(6):3133-3141. PubMed ID: 35641261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Sasaki H; Sueda T
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):419-29. PubMed ID: 23178955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
    Ogawa K; Honda M; Akashi Y; Inagawa S; Kaneda A; Hori S; Owada Y; Ohara Y; Hisakura K; Enomoto T; Shimomura O; Takahashi K; Oda T
    Int J Clin Oncol; 2020 Oct; 25(10):1807-1813. PubMed ID: 32533352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
    Tang H; Qiao C; Lu J; Cheng Y; Dai M; Zhang T; Guo J; Wang Y; Bai C
    Neoplasia; 2022 Dec; 34():100841. PubMed ID: 36265240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
    Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
    World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
    Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
    Sugawara T; Rodriguez Franco S; Sherman S; Kirsch MJ; Colborn K; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Schulick RD; Del Chiaro M
    JAMA Oncol; 2023 Mar; 9(3):316-323. PubMed ID: 36480190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.